Safety of intravitreal bevacizumab in the developing rabbit retina

Retina

Volumn 31, Issue 9, 2011, Pages 1885-1895

  Zayit Soudry, Shiri ^a   Zemel, Esther ^b   Barak, Adiel ^a   Perlman, Ido ^b   Loewenstein, Anat ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

bevacizumab; developing retina; electrophysiological evaluation; rabbit model; toxicity

Indexed keywords

BEVACIZUMAB; GLIAL FIBRILLARY ACIDIC PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAPILLARY; CONTROLLED STUDY; DRUG SAFETY; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; EXPERIMENTAL RABBIT; EYE TOXICITY; FOLLOW UP; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MUELLER CELL; NEWBORN; NONHUMAN; POSTNATAL DEVELOPMENT; RETINA BLOOD VESSEL; RETINA DEVELOPMENT; SINGLE DRUG DOSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL, HUMANIZED; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; GLIAL FIBRILLARY ACIDIC PROTEIN; INTRAVITREAL INJECTIONS; NADPH DEHYDROGENASE; RABBITS; RETINA; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053359588     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821a88e2     Document Type: Article

References (61)

1. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin) a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-335.
2. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor- like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476-1482.
3. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-3993.
4. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res 2004;14(Suppl A):S140-S144.
5. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-4747.
6. Sonmez K, Dresner KA, Capone A Jr., Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008;115:1065-1070.
7. Sato T, Kusaka S, Shimojo H, et al. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009;116:1599-1603.
8. Nonobe NI, Kachi S, Kondo M, et al. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 2009;29:279-285.
9. Kusaka S, Shima C, Shimojyo H, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study. Br J Ophthalmol 2008;92:1450-1455.
10. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061-1063.
11. Chung EJ, Kim JH, Ahn HS, et al. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727-1730.
12. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007;38:233-237.
13. Mintz-Hittner HA, Kuffel RR. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity. Retina 2008;28:831-838.
14. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008; 28:S13-S18.
15. Quiroz-Mercado H,Martinez-CastellanosMA, Hernandez-Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28:S19-S25.
16. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of fulllength humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48:1773-1781.
17. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006;26:882-888.
18. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler JD. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;14:162-164.
19. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
20. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053.
21. Ziemssen F, Luke M, Messias A, et al. Safety monitoring in bevacizumab (Avastin) treatment: Retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2008;28:101-109.
22. Maturi RK, Bleau L, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
23. Henck JW. Developmental neurotoxicology: Testing and interpretation. In: Massaro EJ, ed. Handbook of Neurotoxicology. Vol 2. Totowa, NJ: Humana Press; 2002:3-56.
24. Young RW. The renewal of photoreceptor cell outer segments. J Cell Biol 1967;33:61-72.
25. Fulton AB, Baker BN. The relation of retinal sensitivity and rhodopsin in developing rat retina. Invest Ophthalmol Vis Sci 1984;25:647-651.
26. Bonaventure N, Goswamy S, Karli P. Maturation of the ERG and visual evoked potentials in the rabbit reared in natural environmental lighting conditions. C R Séances Soc Biol Fil 1967;161:689-693.
27. LaVail MM. Kinetics of rod outer segment renewal in the developing mouse retina. J Cell Biol 1973;58:650-661.
28. Schnitzer J. The development of astrocytes and blood vessels in the postnatal rabbit retina. J Neurocytol 1988;17:433-449.
29. Tout S, Ashwell K, Stone J. The development of astrocytes in the albino rabbit retina and their relationship to retinal vasculature. Neurosci Lett 1988;90:241-247.
30. Aguirre GD, Rubin LF, Bistner SI. Development of the canine eye. Am J Vet Res 1972;33:2399-2414.
31. Germer A, Kühnel K, Grosche J, et al. Development of the neonatal rabbit retina in organ culture. 1. Comparison with histogenesis in vivo, and the effect of a gliotoxin (alphaaminoadipic acid). Anat Embryol (Berl) 1997;196:67-79.
32. Zemel E, Loewenstein A, Lazar M, Perlman I. Ocular pigmentation protects the rabbit retina from gentamicininduced toxicity. Invest Ophthalmol Vis Sci 1995;36: 1875-1884.
33. Land RE. The effects of nonabsorbable intrascleral sutures on the growing albino rabbit eye. Am J Ophthalmol 1957;43: 611-614.
34. Goldstein M, Zemel E, Loewenstein A, Perlman I. Retinal toxicity of indocyanine green in albino rabbits. Invest Ophthalmol Vis Sci 2006;47:2100-2107.
35. Hood DC, Birch DG. A computation model of the amplitude and implicit time of the b-wave on the human ERG. Vis Neurosci 1992;8:107-126.
36. Zemel E, Loewenstein A, Lei B, Lazar M, Perlman I. Ocular pigmentation protects the rabbit retina from gentamicin-induced toxicity. Invest Ophthalmol Vis Sci 1995;36:1875-1884.
37. Koistinaho J, Sagar SM. NADPH-diaphorase-reactive neurons in the retina. In: Osborne NN, Chader JP, eds. Progress in Retina and Eye Research. Vol 15. Oxford, United Kingdom: Pergamon Press; 1995:69-87.
38. Nork TM, Ghobrial MW, Peyman GA, Tso MO. Massive retinal gliosis. A reactive proliferation of Muller cells. Arch Ophthalmol 1986;104:1383-1389.
39. Penn JS, Thum LA, Rhem MN, Dell SJ. Effects of oxygen rearing on the electroretinogram and GFA-protein in the rat. Invest Ophthalmol Vis Sci 1988;29:1623-1630.
40. Ekstrom P, Sanyal S, Narfstrom K, Chader GJ, van Veen T. Accumulation of glial fibrillary acidic protein in Muller radial glia during retinal degeneration. Invest Ophthalmol Vis Sci 1988;29:1363-1371.
41. Li Q, Zemel E, Miller B, Perlman I. Early retinal damage in experimental diabetes: Electroretinographical and morphological observations. Exp Eye Res 2002;74:615-625.
42. Chakravarthy U, Stitt AW, McNally J, et al. Nitric oxide synthase activity and expression in retinal capillary endothelial cells and pericytes. Curr Eye Res 1995;14:285-294.
43. Roufail E, Stringer M, Rees S. Nitric oxide synthase immunoreactivity and NADPH diaphorase staining are colocalised in neurons closely associated with the vasculature in rat and human retina. Brain Res 1995;684:36-46.
44. Li Q, Zemel E, Miller B, Perlman I. NADPH diaphorase activity in the rat retina during the early stages of experimental diabetes. Graefes Arch Clin Exp Ophthalmol 2003;241: 747-756.
45. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
46. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998;273: 13313-13316.
47. Gerber HP, McMurtrey A, Kowalski J, et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway, requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-30343.
48. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-165.
49. Guerrin M, Moukadiri H, Chollet P, et al. Vasculotropin/ vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995;164:385-394.
50. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611.
51. Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on the hemodynamics and the cardiac performance. J Cardiovasc Pharmacol 1996;27:838-844.
52. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
53. Nishijima K, Ng YS, Bradley J, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.
54. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: Once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26:943-954.
55. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelail growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-138.
56. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-394.
57. Lambrechts D, Storkebaum E, Carmeliet P. VEGF: Necessary to prevent motoneuron degeneration, sufficient to treat ALS? Trends Mol Med 2004;10:275-282.
58. Breen EC. VEGF in biological control. J Cell Biochem 2007; 102:1358-1367.
59. Ueno S, PeaseME,Wersinger DM, et al. Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 2008; 217:13-22.
60. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92:10457-10461.
61. Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreal bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: A morphologic study. Arch Ophthalmol 2008;126:1161-1163.